Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study - Breast Cancer Research and Treatment Purpose Bone metastases develop in 50–70% of patients with metastatic breast cancer (MBC), with around one-third having bone as only site of distant disease (bone-only [BO]). Standard imaging is frequ...

Is liquid biopsy useful in bone-only metastatic #breastcancer?

Surprise!
✅Pts w bone-only disease are just as likely to have detectable ctDNA
✅ctDNA tumor fraction remains prognostic in bone-only setting

link.springer.com/article/10.1...

@osucccjames.bsky.social

Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - @mtmdphd – DRAFT Update: 12/3/25 v3 cc @grpetersen1 – @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan @JanakiramMurali @jmikhaelmd @End_myeloma @bdermanmd @szusmani @DrOlaLandgren @MyelomaTeacher @VincentRK #ASH25VR

EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma Mantle cell lymphoma (MCL) is a relatively rare B-cell lymphoma subtype, with a higher incidence among males and a median age of 70 years at diagnosis. MCL is characterized by clinically diverse beha...

Pleased to share EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/...
#lymSM @hemasphere-journal.bsky.social

NOW PUBLISHED!! JPCRR Vol. 12, Issue 4: aah.org/jpcrr. No paywalls. Completely #OpenAccess. Sincerest congratulations to @mtmdphd.bsky.social @bzmorgenstern.bsky.social @annzgeorge.bsky.social

Look up NCI and NCORP

Increasing access = increasing cost to increase sites, staff, etc. That is not the mode the government is currently in. Look into NCCCP and NCORP NCI programs for more background

Many publications on this. Short answer is 1) Improve access. 2) Remove I/E criteria that are not necessary. In the US ~85% of cancer patients are treated in the community setting. #ClinicalTrials

Real-World Myeloma Pts Remain Under-Represented in #ClinicalTrials Based on Standard Labs & Baseline Characteristics: Analysis of over 3,000 Pts from @TakedaOncology Insight - @dra_v_hungria et al. @AjaiChari - Abs 1887 #ASH19 ashpublications.org/blood/articl... #mmsm

1) The demographics of MM are usually elderly. 2) Patients are treated by oncologists who monitor side effects -- on or off a study.

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm

Yes. Len and Dara-len are commonly used in MM therapy and tolerated

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

NOW PUBLISHED!! JPCRR Vol. 12, Issue 3: aah.org/jpcrr. No paywalls. Completely #OpenAccess. Sincerest congratulations to @mtmdphd.bsky.social @bzmorgenstern.bsky.social @annzgeorge.bsky.social

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T
Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

Evaluation and comparison of two commercially available targeted next- | OTT Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making Glen J Weiss,1 Brandi R Hoff,1 Robert P Whitehead,1 Ashish Sang...

Evaluation and comparison of two commercially available targeted next-generation sequencing [NGS] platforms to assist oncology decision making [Apr 24, 2015] @drglenweiss.bsky.social et al. OncoTargets and Therapy ow.ly/KtCZ30pBOTq #PrecisionMedicine

Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate & Drug Cost Avoidance [10/20/22] Walters et al. JCO PO @ascocancer.bsky.social ascopubs.org/doi/abs/10.1... #PrecisionMedicine #hpeonc

DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer DDR genes play a key role in detecting and repairing DNA damage and are crucial for maintaining the integrity of the genome [1]. Alterations in DDR genes are associated with genomic instability and in...

DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer [Feb 14, 2025] @KamyaSankar et al. @ReckampK Lung Cancer www.lungcancerjournal.info/article/S016... #lcsm #ImmunoOnc #PrecisionMedicine

Myeloma / Plasma Cell Dyscrasia ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd
- Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani

Myeloma / Plasma Cell Dyscrasia *DRAFT* ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd
- Update: 5/31/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani @CyclingDoctor @MyelomaTeacher

Myeloma / Plasma Cell Dyscrasia *DRAFT* ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - X: @mtmdphd
- Update: 5/29/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani

Heterogeneity in the expression [RNA] of GPRC5D between patients with multiple myeloma - @Phhersh et al. #ASCO25 Abst 7511 meetings.asco.org/abstracts-pr... #mmsm #PrecisionMedicine #cagenome #caxtx n=290 CD138 purified

.@HealthtreeMM Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles & Accelerate Research in Multiple Myeloma [3/10/22] @NSweeneyPhd @AhlstromJenny @FaithEDavies1 @mtmdphd @JCOCCI_ASCO ow.ly/iyIe50Igxhe @myelomacrowd #mmsm

The HealthTree Cure Hub registry: A patient-centered, multicenter approach to advancing multiple myeloma care - Jorge Arturo Hurtado Martínez et al. @HealthTree #ASCO25 Abst e19569 meetings.asco.org/abstracts-pr... #mmsm

Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201 - Landau et al. #ASCO25 #Abst 7508
meetings.asco.org/abstracts-pr... #NCT06097832 #amyloidosis

First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results - van de Donk et al. #ASCO25 Abst 7505
meetings.asco.org/abstracts-pr... #mmsm #caxtx

Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1 - Quach et al. #ASCO25 Abst 7504
meetings.asco.org/abstracts-pr... #mmsm

Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results - Lichtman et al. #ASCO25 Abst 7514
meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx

GEMINI-NSCLC study: Integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients - Palmer et al. #ASCO25 Abst TPS8114 meetings.asco.org/abstracts-pr... @TempusAI @AstraZeneca #LiquidBiopsy #ImmunoOnc #oncorad

Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI) - Park et al. #ASCO25 Abst e17085 meetings.asco.org/abstracts-pr... @TempusAI #pcsm